Evidence map›Paper›PMID 42904061›Full record

ArticlehLife2023

Mouse model for pangolin-origin coronavirus GX/P2V/2017 infection and cross-protection from COVID-19 ZF2001 subunit vaccine.

Xiao Qu, Yunfei Jia, Na Jia, Huahao Fan, Anqi Zheng, Luoyuan Xia, Zhenfei Wang, Di Tian, Sheng Niu, Yu Hu and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in hLife, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Xiao QuCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Yunfei JiaCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Na JiaState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Huahao FanBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Anqi ZhengCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Luoyuan XiaState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Zhenfei WangState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Di TianCenter of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Sheng NiuCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Yu HuCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
Wenxia TianCollege of Veterinary Medicine, Shanxi Agricultural University, Shanxi, China.
Zhihai ChenCenter of Infectious Disease, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
Yigang TongBeijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.
Yuwei GaoInstitute of Military Veterinary Medicine, Academy of Military Medical Sciences, Jilin, China.
Wuchun CaoState Key Laboratory of Pathogen and Biosecurity, Beijing Institute of Microbiology and Epidemiology, Beijing, China.
Qihui WangCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.
George Fu GaoCAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related coronaviruses have been discovered, constituting potential threats to human health. However, it remains unclear whether the currently available vaccines are effective against these coronaviruses. Here, we constructed a wild-type mouse model to evaluate pathogenicity of the SARS-CoV-2-related pangolin coronavirus GX/P2V/2017 and neutralization efficacy of the approved tandem-repeat SARS-CoV-2 spike receptor-binding domain (RBD) vaccine ZF2001. We found that ZF2001-induced cross-reactive and cross-neutralizing antibodies against GX/P2V/2017, and the vaccination alleviated the pathological lung damage caused by GX/P2V/2017 in mice. These results indicate that RBD may work as a promising candidate for pan-coronavirus vaccine development.

Indexed as

mouse modelpangolin-origin coronavirusprotectionvaccineZF2001

Identifiers

PMID42904061
PMCPMC13681681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.